Anika Therapeutics (ANIK) Tops Q2 EPS by 35c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.59 +2.75%
Revenue Growth %: +3.5%
Financial Fact:
Net income: 8.95M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +3.5%
Financial Fact:
Net income: 8.95M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.68, $0.35 better than the analyst estimate of $0.33. Revenue for the quarter came in at $30.5 million versus the consensus estimate of $27.9 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- Worthington Enterprises raises dividend 5%, adds board member
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
